Medscape6d
Topical Psoriasis Therapies: Tapinarof, Roflumilast, and Newer Fixed Combination Topicals Show Robust Efficacy
Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...
Healio5d
Dupilumab linked to reduced risks for psychiatric disorders in atopic dermatitis
Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
This was the stock's fourth consecutive day of losses.
Finanznachrichten3d
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for ...
Investing3d
EMA backs Regeneron’s linvoseltamab for multiple myeloma
TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with a market capitalization of $75.2 billion and annual revenue of $14.2 billion ...
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial ...
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
Yahoo Finance4d
Regeneron makes second bid for blood cancer therapy approval
Regeneron Pharmaceuticals is taking another shot at US Food and Drug Administration (FDA) accelerated approval for odronextamab in relapsed/refractory follicular lymphoma (r/r FL), with the agency ...
Finanznachrichten5d
Regeneron Pharmaceuticals, Inc.: Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...
Investing5d
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
Regeneron Pharmaceuticals (NASDAQ:REGN), a leading biotechnology company with a market capitalization of $77 billion, finds itself at a critical juncture as it navigates challenges to its flagship ...
Insider Monkey6d
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. While stocks initially fell based on worries regarding Trump ...